search
Back to results

Celecoxib as a Post-tonsillectomy Pain Medication

Primary Purpose

Tonsillitis

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Celecoxib
Placebo
Sponsored by
University of Iowa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Tonsillitis focused on measuring Tonsillectomy, Analgesia, Pain measurement, Celecoxib

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age at least 18 years
  • Indication for tonsillectomy (patients undergoing a tonsillectomy as a portion of additional surgical procedures will not be included)
  • Have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • History of bleeding disorders
  • History of liver or kidney dysfunction
  • History of allergy to sulfa containing medications
  • History of lactose intolerance
  • History of asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs
  • Women who are currently pregnant, nursing, or trying to conceive
  • History of allergy or intolerance to acetaminophen or hydrocodone
  • History of allergy to any COX-2 inhibitor, including celecoxib or rofecoxib.
  • PT, PTT, hemoglobin, or hematocrit values that are outside of institutional limits.
  • History of cardiovascular disease
  • Patients currently taking celecoxib

Sites / Locations

  • University of Iowa Hospitals & Clinics

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

A

B

Arm Description

Celecoxib 200 mg tablets

Placebo with same dosing schedule as the active comparator arm

Outcomes

Primary Outcome Measures

Self-reported Pain Score
Pain score as reported by participant, measured on a 10 point scale, where 0 = none and 10 = unbearable, collected once daily.

Secondary Outcome Measures

Self-reported Activity Level
Activity level, reported by participant utilizing a 10-point ordinal scale (0 = no activity, 10 = return to normal activities). Activity level was measured was collected once daily.
Acetaminophen Equivalent Use
Participant reported acetaminophen use and its equivalent. Medication use was collected from reported participant journals.
Incidence of Post-operative Hemorrhage
The incidence of post-operative hemorrhage, defined as post-operative bleeding requiring medical intervention or hospitalization during the 10 day post-operative follow-up period.
Total Morphine Equivalent
Participant reported mophine equivalent use

Full Information

First Posted
December 20, 2007
Last Updated
February 12, 2017
Sponsor
University of Iowa
Collaborators
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00583453
Brief Title
Celecoxib as a Post-tonsillectomy Pain Medication
Official Title
Perioperative Use of Celecoxib to Improve Pain Control in Patients Undergoing Tonsillectomy: a Randomized, Double Blind, Placebo-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Iowa
Collaborators
Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The hypothesis is that celecoxib effectively reduces pain after a tonsillectomy and reduces post-operative narcotic use. To test this hypothesis, the study is placebo controlled (sugar pill). Half of the participants will receive a sugar pill, half will not. All participants will receive the standard post-operative pain medications. We ask participants to log the amount of medications they use daily, and the amount of pain they have each day. It is hoped that celecoxib will reduce the amount of post-operative pain medication needed.
Detailed Description
Post-tonsillectomy pain is typically controlled through narcotic medications, such as Lortab elixir. Despite its standard use, this pain control is typically not as effective as a non-steroidal anti-inflammatory medication (NSAID). The problem with using NSAIDs for post-tonsillectomy operative pain is the significant increased risk of rebleeding. Celecoxib is an NSAID that is a COX-2 inhibitor; the drug is designed to act as an NSAID without the increased risk of rebleeding or hemorrhage. This study is a double blind, randomized study; neither the study participant or the study investigator knows if the participant is receiving celecoxib or a placebo (sugar pill). The blinded list is maintained by the research pharmacists and can be unblinded when needed (such as in an emergency). Participants begin taking the study medication the night before surgery and continue through 10 days post-operative. Participants are asked to complete a journal that catalogs the amount of standard post-operative medications taken, the amount of pain experienced, and any other comments. Participants are contacted by phone at 5 and 10 days post-op. Study participation ends at the standard 3-week post-operative check-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tonsillitis
Keywords
Tonsillectomy, Analgesia, Pain measurement, Celecoxib

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Active Comparator
Arm Description
Celecoxib 200 mg tablets
Arm Title
B
Arm Type
Placebo Comparator
Arm Description
Placebo with same dosing schedule as the active comparator arm
Intervention Type
Drug
Intervention Name(s)
Celecoxib
Other Intervention Name(s)
Celebrex
Intervention Description
Celecoxib 200 mg capsule capsule the night before surgery capsules the morning of surgery 1 capsule the night of surgery 1 capsule twice daily for 10 days immediately after the surgery
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo capsule capsule the night before surgery capsules the morning of surgery 1 capsule the night of surgery 1 capsule twice daily for 10 days immediately after the surgery
Primary Outcome Measure Information:
Title
Self-reported Pain Score
Description
Pain score as reported by participant, measured on a 10 point scale, where 0 = none and 10 = unbearable, collected once daily.
Time Frame
day of procedure through post-operative day 10
Secondary Outcome Measure Information:
Title
Self-reported Activity Level
Description
Activity level, reported by participant utilizing a 10-point ordinal scale (0 = no activity, 10 = return to normal activities). Activity level was measured was collected once daily.
Time Frame
From operative day through 10 days post-operative
Title
Acetaminophen Equivalent Use
Description
Participant reported acetaminophen use and its equivalent. Medication use was collected from reported participant journals.
Time Frame
From operative day through 10 days post-operative
Title
Incidence of Post-operative Hemorrhage
Description
The incidence of post-operative hemorrhage, defined as post-operative bleeding requiring medical intervention or hospitalization during the 10 day post-operative follow-up period.
Time Frame
From operative day through 10 days post-operative
Title
Total Morphine Equivalent
Description
Participant reported mophine equivalent use
Time Frame
From operative day through 10 days post-operative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age at least 18 years Indication for tonsillectomy (patients undergoing a tonsillectomy as a portion of additional surgical procedures will not be included) Have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: History of bleeding disorders History of liver or kidney dysfunction History of allergy to sulfa containing medications History of lactose intolerance History of asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs Women who are currently pregnant, nursing, or trying to conceive History of allergy or intolerance to acetaminophen or hydrocodone History of allergy to any COX-2 inhibitor, including celecoxib or rofecoxib. PT, PTT, hemoglobin, or hematocrit values that are outside of institutional limits. History of cardiovascular disease Patients currently taking celecoxib
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Douglas VanDaele, MD
Organizational Affiliation
Department of Otolaryngology-Head & Neck Surgery
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa Hospitals & Clinics
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be uploaded through clinicaltrials.gov data tables
Citations:
PubMed Identifier
27357971
Citation
Van Daele DJ, Bodeker KL, Trask DK. Celecoxib Versus Placebo in Tonsillectomy: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial. Ann Otol Rhinol Laryngol. 2016 Oct;125(10):785-800. doi: 10.1177/0003489416654707. Epub 2016 Jun 29.
Results Reference
result

Learn more about this trial

Celecoxib as a Post-tonsillectomy Pain Medication

We'll reach out to this number within 24 hrs